Baseline characteristics
| Variable . | All patients N = 12 (%) . |
|---|---|
| Median age, range (y) | 68 (52-86) |
| Sex, n (%) | |
| Males | 7 (58) |
| Females | 5 (42) |
| BMI < 30 kg/m2, n (%) | 8 (67) |
| ECOG PS, n (%) | |
| 0 | 6 (50) |
| 1 | 6 (50) |
| B symptoms, n (%) | 3 (25) |
| MZL subtype, n (%) | |
| EMZL | 3 (25) |
| NMZL | 5 (42) |
| SMZL | 4 (33) |
| Stage, n (%) | |
| I-II | 2 (17) |
| III-IV | 10 (83) |
| WBC, ×103/μL, median, range | 7.9 (14.8-32.4) |
| Hgb, g/dL, median, range | 12.1 (10.1-15) |
| LDH > ULN | 3 (25) |
| Albumin < ULN | 2 (17) |
| BM involvement | |
| No | 4 (33%) |
| Yes | 6 (50%) |
| Not done | 2 (17) |
| Monoclonal protein | |
| No | 6 (50) |
| Yes | 2 (17) |
| Not checked | 4 (33) |
| 17p del/TP53 mutation | |
| No | 5 (42) |
| Yes | 0 (0) |
| Not checked | 7 (58) |
| Complex cytogenetics∗ | |
| No | 5 (83) |
| Yes | 1 (17) |
| Variable . | All patients N = 12 (%) . |
|---|---|
| Median age, range (y) | 68 (52-86) |
| Sex, n (%) | |
| Males | 7 (58) |
| Females | 5 (42) |
| BMI < 30 kg/m2, n (%) | 8 (67) |
| ECOG PS, n (%) | |
| 0 | 6 (50) |
| 1 | 6 (50) |
| B symptoms, n (%) | 3 (25) |
| MZL subtype, n (%) | |
| EMZL | 3 (25) |
| NMZL | 5 (42) |
| SMZL | 4 (33) |
| Stage, n (%) | |
| I-II | 2 (17) |
| III-IV | 10 (83) |
| WBC, ×103/μL, median, range | 7.9 (14.8-32.4) |
| Hgb, g/dL, median, range | 12.1 (10.1-15) |
| LDH > ULN | 3 (25) |
| Albumin < ULN | 2 (17) |
| BM involvement | |
| No | 4 (33%) |
| Yes | 6 (50%) |
| Not done | 2 (17) |
| Monoclonal protein | |
| No | 6 (50) |
| Yes | 2 (17) |
| Not checked | 4 (33) |
| 17p del/TP53 mutation | |
| No | 5 (42) |
| Yes | 0 (0) |
| Not checked | 7 (58) |
| Complex cytogenetics∗ | |
| No | 5 (83) |
| Yes | 1 (17) |
BM, bone marrow; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; EMZL, extranodal MZL; Hgb, hemoglobin; LDH, lactate dehydrogenase; NMZL, nodal MZL; PS, performance status; SMZL, splenic MZL; ULN, upper limit of normal per institutional standard; WBC, white blood cell.
Only among those who had BM involvement.